Universe Pharmaceuticals (UPC) Short term Debt (2021 - 2025)

Universe Pharmaceuticals (UPC) has 5 years of Short term Debt data on file, last reported at $7.1 billion in Q3 2025.

• For the quarter ending Q3 2025, Short term Debt rose 22.08% year-over-year to $7.1 billion; the trailing twelve-month figure through Sep 2025 stood at $7.1 billion (up 22.08% YoY), and the FY2025 full-year result was $7.1 billion, up 22.08% from the prior year.
• Short term Debt rose to $7.1 billion in Q3 2025, from $5.9 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $7.1 billion in Q3 2025 to a low of $19723.0 in Q3 2021.
• A 5-year average of $2.6 billion and a median of $5.5 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt surged 106726.27% in 2024 and gained 22.08% in 2025, its largest moves.
• Tracing UPC's Short term Debt over 5 years: stood at $19723.0 in 2021, then soared by 17033.62% to $3.4 million in 2022, then surged by 62.24% to $5.5 million in 2023, then surged by 106726.27% to $5.9 billion in 2024, then climbed by 22.08% to $7.1 billion in 2025.
• Business Quant data shows UPC's Short term Debt at $7.1 billion in Q3 2025, $5.9 billion in Q3 2024, and $5.5 million in Q3 2023.